

**PARTICULARS TO APPEAR ON <THE OUTER PACKAGE> 100 TABLET  
CARTON**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprieve 20 mg Tablets

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

A white/off white circular tablet for oral administration containing 20 mg Carprofen.

**3. PHARMACEUTICAL FORM**

Tablets

**4. PACKAGE SIZE**

100 Tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION(S)**

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs.

Carprieve Tablets can also be used in the management of post-operative pain.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

For oral administration.

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given in two equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response. See maintenance dose table below:

Maintenance Dose Table	Number of tablets per dose	
Bodyweight (kg)	20 mg	50 mg
5.0	●	-
10.0	●●	-
12.5	-	●
15.0	●●	-
20.0	●●●	-
25.0	-	●●
37.5	-	●●●
50	-	●●●●

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets.

## **8. WITHDRAWAL PERIOD**

Nil

## **9. SPECIAL WARNING(S), IF NECESSARY**

**The use of Carprieve Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.**

Do not exceed the stated dose.

Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided.

In the absence of any specific studies in pregnant bitches, such use is not indicated.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

### **Operator Warnings**

None

## **10. EXPIRY DATE**

Exp.: dd/mm/yy

## **11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

Store in a dry place.

Protect from light.

## **12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE [Distribution category]**

**For animal treatment only.**

POM-V
-------

 To be supplied only on veterinary prescription

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

**Keep out of the reach and sight of children.**

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**Manufactured by:**

Norbrook Laboratories Limited  
Station Works  
Newry  
Co. Down, BT35 6JP  
Northern Ireland

**Distributed by:**

Norbrook Laboratories Limited  
Carnbane Industrial Estate  
Newry  
Co. Down  
BT35 6QQ  
Northern Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

ManA 2000  
Vm 02000/4220

**17. MANUFACTURER’S BATCH NUMBER**

B.N.:

DOM:

**UK AUTHORISED VETERINARY MEDICINAL PRODUCT**

**PARTICULARS TO APPEAR ON <THE IMMEDIATE PACKAGE> 100 TABLET  
BASE LABEL/EXPANDING LABEL (PAGE 1)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprieve 20 mg Tablets

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each tablet contains: Carprofen 20 mg

**3. PHARMACEUTICAL FORM**

Tablets

**4. PACKAGE SIZE**

100 Tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION(S)**

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs.

Carprieve Tablets can also be used in the management of post-operative pain.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

For oral administration.

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given in two equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response. See maintenance dose table below:

Maintenance Dose Tablet	Number of tablets per dose	
	20 mg	50 mg
5.0	●	-
10.0	●●	-
12.5	-	●
15.0	●●	-
20.0	●●●	-
25.0	-	●●
37.5	-	●●●
50	-	●●●●

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets.

## **8. WITHDRAWAL PERIOD**

Nil

## **9. SPECIAL WARNING(S), IF NECESSARY**

Please refer to enclosed expanding label for further details

### **Operator Warnings**

None

## **10. EXPIRY DATE**

Exp.: dd/mm/yy

## **11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.  
Store in a dry place.  
Protect from light.

## **12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

## **13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE [Distribution category]**

**For animal treatment only.**

POM-V To be supplied only on veterinary prescription

## **14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

**Keep out of the reach and sight of children.**

## **15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**Manufactured by:**

Norbrook Laboratories Limited  
Station Works  
Newry  
Co. Down, BT35 6JP  
Northern Ireland

**Distributed by:**

Norbrook Laboratories Limited  
Carnbane Industrial Estate  
Newry  
Co. Down  
BT35 6QQ  
Northern Ireland

## **16. MARKETING AUTHORISATION NUMBER(S)**

ManA 2000  
Vm 02000/4220

## **17. MANUFACTURER'S BATCH NUMBER**

B.N.:

DOM:

**UK AUTHORISED VETERINARY MEDICINAL PRODUCT**

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**  
**{NATURE/TYPE}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprieve 20mg Tablets

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Norbrook Laboratories Limited.

**3. EXPIRY DATE**

Exp: dd/mm/yy

**4. BATCH NUMBER**

Bn.:

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For Animal Treatment Only.

**PACKAGE LEAFLET FOR:**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Norbrook Laboratories Limited  
Station Works  
Newry  
Co. Down, BT35 6JP  
Northern Ireland

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprieve 20 mg Tablets

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

A white/off white circular tablet for oral administration. Carprieve Tablets are available in two strengths with the following active composition:

20 mg Carprofen  
50 mg Carprofen

**4. INDICATION(S)**

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs.

Carprieve Tablets can also be used in the management of post-operative pain.

**5. CONTRAINDICATIONS**

The use of Carprieve Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.

**6. ADVERSE REACTIONS**

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

**7. TARGET SPECIES**

Dogs



**8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given in two equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response. See maintenance dose table below:

Maintenance Dose Table	Number of tablets per dose	
	20 mg	50 mg
Bodyweight (kg)		
5.0	●	-
10.0	●●	-
12.5	-	●
15.0	●●	-
20.0	●●●	-
25.0	-	●●
37.5	-	●●●
50	-	●●●●

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.

To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets.

**9. ADVICE ON CORRECT ADMINISTRATION**

For oral administration to dogs.

**10. WITHDRAWAL PERIOD**

Nil

**11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the reach and sight of children.  
Do not store above 25°C.  
Store in a dry place.  
Protect from light

**12. SPECIAL WARNINGS**

Do not exceed the stated dose.  
Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

Concurrent administration of potential nephrotoxic drugs should be avoided.

In the absence of any specific studies in pregnant bitches, such use is not indicated.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

**Operator Warnings:**

None

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

October 2022

**15. OTHER INFORMATION**

Carprieve Tablets 20 mg	Vm: 02000/4220
Carprieve Tablets 50 mg	Vm: 02000/4221

**PACKAGE QUANTITIES:**

100 x 20 mg tablets per tub or carton (containing 10 blister strips)

100 x 50 mg tablets per tub or carton (containing 10 blister strips)

500 x 50 mg tablets per tub or carton (containing 5 x 10 blister strips)

Not all package sizes may be presented.

**DISTRIBUTED BY:**

Norbrook Laboratories Limited  
Carnbane Industrial Estate  
Newry  
Co. Down  
BT35 6QQ  
Northern Ireland

POM-V

To be supplied only by veterinary prescription

**MINIMUM PARTICULARS TO APPEAR ON THE LABEL WHERE THERE IS NO PACKAGE LEAFLET, EXPANDING VIAL LABEL PAGE 2-10**

*[The guidance contained below is national specific only and should be used in addition to EU QRD template guidance for both the Package Leaflet AND the Outer/Immediate package, available on the EMA website.]*

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Norbrook Laboratories Limited  
Station Works  
Newry  
Co. Down  
BT35 6JP

**Distributed by:**

Norbrook Laboratories Limited  
Carnbane Industrial Estate  
Newry  
Co. Down  
BT35 6QQ  
Northern Ireland

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprieve 20mg Tablets

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

A white/off white tablet for oral administration. Carprieve Tablets are available in two strengths with the following active composition:

20 mg Carprofen  
50 mg Carprofen

**4. PHARMACEUTICAL FORM**

Tablet

**5. PACKAGE SIZE**

100 Tablets

**6. INDICATION(S)**

For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs.

Carprieve Tablets can also be used in the management of post-operative pain.

## 7. CONTRAINDICATIONS

The use of Carprieve Tablets is contraindicated in the cat, and the inadvertent administration of oral carprofen tablets may induce life-threatening conditions in this species.

## 8. ADVERSE REACTIONS

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## 9. TARGET SPECIES

Dogs

## 10. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

An initial dose of 2 to 4 mg carprofen/kg bodyweight/day is recommended to be given in 2 equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response: see maintenance dose table below:

Maintenance Dose Table Bodyweight (kg)	Number of tablets per dose	
	20 mg	50 mg
5.0	●	-
10.0	●	-
12.5	-	●
15.0	●●	-
20.0	●●	-
25.0	-	●
37.5	-	●●
50	-	●●

## 10. ADVICE ON CORRECT ADMINISTRATION

For oral administration.

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision. To extend analgesic cover post-operatively, parenteral administration of carprofen, may be followed with Carprieve Tablets

## **12. WITHDRAWAL PERIOD**

Not applicable

## **13. SPECIAL STORAGE PRECAUTIONS**

Keep out of the reach and sight of children.  
Do not store above 25°C.  
Store in a dry place.  
Protect from light

## **14. SPECIAL WARNING(S)**

Do not exceed the stated dose.  
Do not administer NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.  
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.  
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.  
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.  
Concurrent administration of potential nephrotoxic drugs should be avoided.  
In the absence of any specific studies in pregnant bitches, such use is not indicated.  
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

## **15. EXPIRY DATE**

EXP:

## **16. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Any unused product or waste material should be disposed of in accordance with national requirements.

## **16. DATE ON WHICH THE LABEL WAS LAST APPROVED**

October 2022

**18. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

**For Animal Treatment only.**

POM-V

To be supplied only by veterinary prescription.

**19. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

**Keep out of the sight and reach of children**

**20. MARKETING AUTHORISATION NUMBER(S)**

Vm 02000/4220

**21. MANUFACTURER’S BATCH NUMBER**

B.N.:

**<22. OTHER INFORMATION>**

**PACKAGE QUANTITIES:**

100 x 20 mg tablets per tub  
100 x 50 mg tablets per tub  
500 x 50 mg tablets per tub  
Not all pack sizes may be marketed.

**UK AUTHORISED VETERINARY MEDICINAL PRODUCT**

Approved 28 October 2022

